William Blair analyst Andrew Brackmann has reiterated their bullish stance on HOLX stock, giving a Buy rating on August 11.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Brackmann has given his Buy rating due to a combination of factors, including Hologic’s anticipated reacceleration in revenue and earnings growth. The company’s breast health segment is particularly crucial for this growth, and current trends suggest that Hologic is on track to achieve its goals. Management has indicated that Hologic is expected to return to a mid-single-digit top-line growth, which appears attainable based on the company’s strategic plans.
Furthermore, Hologic’s stock is currently trading at a valuation below its 10-year average, suggesting potential for upward movement. The possibility of mergers and acquisitions provides a safety net for the stock’s valuation, which could lead to multiple expansions and modest improvements in financial metrics. These factors collectively support the Buy rating, as they indicate a favorable outlook for the company’s stock performance in the coming quarters.
In another report released on August 11, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $77.00 price target.